{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:15:56Z","timestamp":1778580956979,"version":"3.51.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Demonstration Construction Project for Research-Oriented Wards of Beijing YouAn Hospital of Capital Medical University","award":["2-1-1-2n-03-10-03"],"award-info":[{"award-number":["2-1-1-2n-03-10-03"]}]},{"name":"Beijing Research Ward Excellence Program","award":["BRWEP2024W042180103"],"award-info":[{"award-number":["BRWEP2024W042180103"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072271"],"award-info":[{"award-number":["82072271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82241072"],"award-info":[{"award-number":["82241072"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The High-Level Public Health Technical Personnel Construction Project","award":["2022-1-007"],"award-info":[{"award-number":["2022-1-007"]}]},{"DOI":"10.13039\/100013594","name":"Alpha Foundation for the Improvement of Mine Safety and Health","doi-asserted-by":"crossref","award":["2022-1-1151"],"award-info":[{"award-number":["2022-1-1151"]}],"id":[{"id":"10.13039\/100013594","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Research and Translational Application of Clinical Characteristic Diagnostic and Treatment Techniques in Capital City","award":["Z221100007422055"],"award-info":[{"award-number":["Z221100007422055"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Biktarvy is an effective antiviral drug for patients with HIV. However, owing to its long-term use and poor patient adherence, sustained and effective Biktarvy treatment is consistently limited by insufficient in vivo drug concentrations. Liquid chromatography (LC)\u2013tandem mass spectrometry\u2013based therapeutic drug monitoring is a common tool for identifying inadequate dosages and preventing antiviral failure. However, this tool requires expensive instruments and reagents, which is a major limitation in resource-limited regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A simple and economical liquid chromatography\u2013ultraviolet method was established and validated for simultaneous quantification of Biktarvy-derived bictegravir (BIC) and emtricitabine (FTC) in human plasma. The samples were pretreated through protein precipitation with acetonitrile, and chromatographic separation was performed on a C18 analytical column with gradient elution at a flow rate of 1.0 mL\/min. The total runtime for each sample was 15.0 minutes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The method exhibited good linearity within the range of 0.5\u201320.0 mcg\/mL for both BIC and FTC. The selectivity, lower limit of quantification, specificity, precision, accuracy, recovery, stability, and dilution integrity were validated, and all satisfied the requirements of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use: Bioanalytical method validation and study sample analysis (2022 edition) and the Chinese Pharmacopoeia for bioanalytical method validation (2015 edition). Furthermore, the method exhibited satisfactory performance, with BIC and FTC concentrations ranging between 0.80 and 6.99 mcg\/mL and 0.53\u20134.57 mcg\/mL, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A simple and economical liquid chromatography\u2013ultraviolet method was successfully developed for simultaneous quantification of BIC and FTC in human plasma. This method can be extensively used in therapeutic drug monitoring, as in the case of MS-based instrumental deficiency or damage, and in pharmacokinetic studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001388","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:00:24Z","timestamp":1758628824000},"page":"350-357","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Simultaneous Quantification of Bictegravir and Emtricitabine Using a Simple and Economical Liquid Chromatography\u2013Ultraviolet Method for Therapeutic Drug Monitoring in Patients With Human Immunodeficiency Virus"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0749-6718","authenticated-orcid":false,"given":"Haihong","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing YouAn Hospital of Capital Medical University, Beijing, PR China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory for HIV\/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing YouAn Hospital of Capital Medical University, Beijing, PR China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihe","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing YouAn Hospital of Capital Medical University, Beijing, PR China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory for HIV\/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing YouAn Hospital of Capital Medical University, Beijing, PR China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory for HIV\/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing YouAn Hospital of Capital Medical University, Beijing, PR China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing YouAn Hospital of Capital Medical University, Beijing, PR China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"R1-20260508","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1016\/S2352-3018(22)00327-7","article-title":"We should not stop considering HIV drug resistance testing at failure of first-line antiretroviral therapy","volume":"10","author":"Kantor","year":"2023","journal-title":"Lancet HIV"},{"key":"R2-20260508","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1473-3099(18)30647-9","article-title":"Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis","volume":"19","author":"Hemelaar","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"R3-20260508","doi-asserted-by":"crossref","first-page":"13596535211067599","DOI":"10.1177\/13596535211067599","article-title":"The best backbone for HIV prevention, treatment, and elimination: emtricitabine+tenofovir","volume":"27","author":"Schinazi","year":"2022","journal-title":"Antivir Ther."},{"key":"R4-20260508","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/cells13080672","article-title":"HIV Infection, antiretroviral drugs, and the vascular endothelium","volume":"13","author":"Kanmogne","year":"2024","journal-title":"Cells"},{"key":"R5-20260508","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3390\/v16040582","article-title":"Cardiometabolic differences in people living with HIV receiving integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors: implications for current ART strategies","volume":"16","author":"Vos","year":"2024","journal-title":"Viruses"},{"key":"R6-20260508","doi-asserted-by":"crossref","first-page":"3946320231207514","DOI":"10.1177\/03946320231207514","article-title":"Revolutionizing antiretroviral therapy for human immunodeficiency virus\/AIDS: a computational approach using molecular docking, virtual screening, and 3D pharmacophore building to address therapeutic failure and propose highly effective candidates","volume":"37","author":"Annan","year":"2023","journal-title":"Int J Immunopathol Pharmacol."},{"key":"R7-20260508","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/hiv.13386","article-title":"Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: a pooled analysis from three international phase III randomized trials","volume":"24","author":"Avihingsanon","year":"2023","journal-title":"HIV Med."},{"key":"R8-20260508","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1097\/CM9.0000000000003383","article-title":"Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2024 edition)","volume":"137","year":"2024","journal-title":"Chin Med J (Engl)."},{"key":"R9-20260508","doi-asserted-by":"crossref","first-page":"115862","DOI":"10.1016\/j.bcp.2023.115862","article-title":"Biktarvy for the treatment of HIV infection: progress and prospects","volume":"217","author":"De Clercq","year":"2023","journal-title":"Biochem Pharmacol."},{"key":"R10-20260508","doi-asserted-by":"crossref","first-page":"13596535231159030","DOI":"10.1177\/13596535231159030","article-title":"Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: a scoping review","volume":"28","author":"Peters","year":"2023","journal-title":"Antivir Ther."},{"key":"R11-20260508","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1358\/dot.2019.55.11.3068796","article-title":"Bictegravir, a novel integrase inhibitor for the treatment of HIV infection","volume":"55","author":"Zeuli","year":"2019","journal-title":"Drugs Today (Barc)."},{"key":"R12-20260508","first-page":"e56441","article-title":"Navigating the antiretroviral therapy switch conundrum: unveiling the dilemma of drug resistance and disease progression in HIV\/AIDS","volume":"16","author":"Sharma","year":"2024","journal-title":"Cureus"},{"key":"R13-20260508","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/idr15060069","article-title":"Bictegravir\/tenofovir alafenamide\/emtricitabine: a real-life experience in people living with HIV (PLWH)","volume":"15","author":"Gidari","year":"2023","journal-title":"Infect Dis Rep."},{"key":"R14-20260508","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/14737159.2024.2312122","article-title":"Point-of-care urine tenofovir monitoring of adherence to drive interventions for HIV treatment and prevention","volume":"24","author":"Spinelli","year":"2024","journal-title":"Expert Rev Mol Diagn."},{"key":"R15-20260508","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11904-020-00502-5","article-title":"Approaches to objectively measure antiretroviral medication adherence and drive adherence interventions","volume":"17","author":"Spinelli","year":"2020","journal-title":"Curr HIV\/AIDS Rep."},{"key":"R16-20260508","doi-asserted-by":"crossref","first-page":"115932","DOI":"10.1016\/j.jpba.2023.115932","article-title":"Development and validation of an ultra-high-performance liquid chromatography-tandem mass spectrometry method to quantify antiretroviral drug concentrations in human plasma for therapeutic monitoring","volume":"240","author":"West","year":"2024","journal-title":"J Pharm Biomed Anal."},{"key":"R17-20260508","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1111\/bcp.14344","article-title":"Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients","volume":"86","author":"N\u00e9ant","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"R18-20260508","doi-asserted-by":"crossref","first-page":"e4506","DOI":"10.1002\/jms.4506","article-title":"Development and validation of a multiplex UHPLC-MS\/MS assay with stable isotopic internal standards for monitoring the plasma concentrations of antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV","volume":"55","author":"Courlet","year":"2020","journal-title":"J Mass Spectrom."},{"key":"R19-20260508","doi-asserted-by":"crossref","first-page":"113057","DOI":"10.1016\/j.jpba.2019.113057","article-title":"UPLC-MS\/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma","volume":"181","author":"Gouget","year":"2020","journal-title":"J Pharm Biomed Anal."},{"key":"R20-20260508","doi-asserted-by":"crossref","first-page":"e4379","DOI":"10.1002\/bmc.4379","article-title":"Development and validation of LC-MS\/MS method for quantification of bictegravir in human plasma and its application in an intracellular uptake study","volume":"33","author":"Prathiunk","year":"2019","journal-title":"Biomed Chromatogr."},{"key":"R21-20260508","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/ph14050460","article-title":"Development and validation of an up-to-date highly sensitive UHPLC-MS\/MS method for the simultaneous quantification of current anti-HIV nucleoside analogues in human plasma","volume":"14","author":"De Nicol\u00f2","year":"2021","journal-title":"Pharmaceuticals (Basel)."},{"key":"R22-20260508","doi-asserted-by":"crossref","first-page":"115084","DOI":"10.1016\/j.ab.2023.115084","article-title":"LC-QQQ-MS based intracellular quantification of bictegravir in peripheral blood mononuclear cells and plasma","volume":"667","author":"Jadav","year":"2023","journal-title":"Anal Biochem."},{"key":"R23-20260508","doi-asserted-by":"crossref","first-page":"115010","DOI":"10.1016\/j.jpba.2022.115010","article-title":"Validation of an LC-MS\/MS assay for the simultaneous determination of bictegravir, doravirine, and raltegravir in human plasma","volume":"220","author":"Schauer","year":"2022","journal-title":"J Pharm Biomed Anal."},{"key":"R24-20260508","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jchromb.2009.05.029","article-title":"The simultaneous assay of tenofovir and emtricitabine in plasma using LC\/MS\/MS and isotopically labeled internal standards","volume":"877","author":"Delahunty","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R26-20260508","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jpba.2018.04.035","article-title":"Development and validation of an LC-MS\/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid","volume":"156","author":"Ocque","year":"2018","journal-title":"J Pharm Biomed Anal."},{"key":"R27-20260508","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1186\/s12889-024-18730-4","article-title":"Prevalence trends of anemia impairment in adolescents and young adults with HIV\/AIDS","volume":"24","author":"Li","year":"2024","journal-title":"BMC Public Health"},{"key":"R28-20260508","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.3390\/ijms25052685","article-title":"Development and validation of an HPLC-UV method for the quantification of acyclovir and ganciclovir in the plasma of pediatric immunocompromised patients","volume":"25","author":"Franzin","year":"2024","journal-title":"Int J Mol Sci."},{"key":"R29-20260508","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000003783","article-title":"A study of the pharmacokinetics, safety, and efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed pregnant women with HIV","volume":"38","author":"Zhang","year":"2024","journal-title":"AIDS"},{"key":"R30-20260508","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/QAI.0000000000002765","article-title":"Brief Report: pharmacokinetics of bictegravir and tenofovir in combination with darunavir\/cobicistat in treatment-experienced persons with HIV","volume":"88","author":"Salama","year":"2021","journal-title":"J Acquir Immune Defic Syndr."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:42:53Z","timestamp":1778578973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001388","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"2025-03-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}